Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 23, Issue 3, 2012, Pages

  Baudry Simner, Patricia J ^a,b   Singh, Amanpreet ^a   Karlowsky, James A ^a,b   Hoban, Daryl J ^a,b   Zhanel, George G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Ciprofloxacin; Escherichia coli; Fluoroquinolone; Plasmid mediated quinolone resistance; Quinolone resistance determining region

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PROTEIN PARC; QUINOLONE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; ESCHERICHIA COLI; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION;

EID: 84866768301     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/569093     Document Type: Article

References (21)

1. Zhanel GG, Karlowsky JA, DeCorby M, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2007). Can J Infect Dis Med Microbiol 2009;20(Suppl A):9A-19A.
2. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120-6. (Pubitemid 40962482)
3. Cattoir V, Nordmann P. Plasmid-mediated quinolone resistance in gram-negative bacterial species: An update. Curr Med Chem 2009;16:1028-46.
4. Courvalin P. Plasmid-mediated 4-quinolone resistance: A real or apparent absence Antimicrob Agents Chemother 1990;34:681-4. (Pubitemid 20142380)
5. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem Clin Microbiol Infect 2008;14:295-7. (Pubitemid 351356518)
6. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006;6:629-40. (Pubitemid 44427732)
7. Yumane K SS, Wachino J, Arakawa Y. Plasmid-mediated fluoroquinolone resistance genes, qepA and qnr, among Escherichia coli clinical isolates in Japan. Antimicrob Agents Chemother 2008;52:1564-6. (Pubitemid 351522037)
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 16th Informational Supplement. CLSI document M100-S16. Wayne, 2006.
9. Baudry PJ, Nichol K, DeCorby M, et al. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: The 1st report of QepA in North America. Diagn Microbiol Infect Dis 2009;63:319-26.
10. Ruiz J. Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003;51:1109-17. (Pubitemid 36622067)
11. Rodriguez-Martinez JM, Velasco C, Garcia I, et al. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob Agents Chemother 2007;51:2236-9. (Pubitemid 46903126)
12. Poirel L, Pitout JD, Calvo L, et al. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob Agents Chemother 2006;50:1525-7.
13. Park CH, Robicsek A, Jacoby GA, et al. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother 2006;50:3953-5. (Pubitemid 44684926)
14. Pitout JD, Wei Y, Church DL, Gregson DB. Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: The emergence of aac(6′)-Ib-cr. J Antimicrob Chemother 2009;61:999-1002. (Pubitemid 351524438)
15. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009;53:235-41.
16. Cavaco LM, Aarestrup FM. Evaluation of quinolones for detection of acquired quinolone resistance, including the new transmissible resistance mechanisms (qnrA, qnrB, qnrS and aac(6′)Ib-cr) in Escherichia coli and Salmonella enterica and determinations of wild type distributions. J Clin Microbiol 2009;47:2751-8.
17. Karah N, Laurent P, Bengtsson S, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn Microbiol Infect Dis 2010;66:425-31.
18. Jiang Y, Zhou Z, Qian Y, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother 2008;61:1003-6. (Pubitemid 351524439)
19. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 2006;58:665-8. (Pubitemid 44288136)
20. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31(Suppl 2):S24-8. (Pubitemid 32269605)
21. Nicolle L, Duckworth H, Sitar D, et al. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. Int J Antimicrob Agents 2008;31:287-9.